Randomized Multicenter, Phase III Trial Evaluating the Safety of 2 Schedules of Cabazitaxel (Bi-weekly Versus Tri-weekly) Plus Prednisone in Elderly Men (≥ 70 Years) With mCRPC Previously Treated With a Docetaxel-containing Regimen
Phase of Trial: Phase III
Latest Information Update: 05 Jun 2017
At a glance
- Drugs Cabazitaxel (Primary) ; Granulocyte colony-stimulating factors (Primary) ; Prednisone (Primary)
- Indications Prostate cancer
- Focus Adverse reactions
- Acronyms CABASTY
- 30 May 2017 Status changed from not yet recruiting to recruiting.
- 03 Feb 2017 Planned initiation date changed from 1 Nov 2016 to 1 Mar 2016.
- 15 Nov 2016 New trial record